Hangzhou Biotest Biotech Co.,Ltd. (SHA:688767)

Hangzhou Biotest Biotech Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	472	519.74	435.93	1,894	1,811	855.9
Other Revenue	39.67	39.67	6.18	7.23	7.09	9.47
Revenue	511.66	559.4	442.11	1,901	1,818	865.37
Revenue Growth (YoY)	7.93%	26.53%	-76.74%	4.57%	110.09%	314.37%
Cost of Revenue	259.08	286.6	269.6	940.21	705.47	242.57
Gross Profit	252.58	272.81	172.51	960.93	1,113	622.8
Selling, General & Admin	93.06	85.9	79.21	86.09	69.63	42.36
Research & Development	64.05	63.57	80.48	108.21	61.92	41.32
Other Operating Expenses	9.58	7.05	4.95	19.49	16.84	9.69
Operating Expenses	168.9	160.05	168.31	208.2	151.61	96.6
Operating Income	83.68	112.76	4.21	752.73	961	526.2
Interest Expense	-0.03	-0.03	-0.14	-0.19	-0.68	-0.47
Interest & Investment Income	50.54	57.28	76.9	51.91	15.36	1.4
Currency Exchange Gain (Loss)	11.44	11.44	13.07	111.92	-15.48	-17.16
Other Non Operating Income (Expenses)	-1.92	-1.92	-0.59	-1.1	-0.87	-0.67
EBT Excluding Unusual Items	143.71	179.52	93.46	915.26	959.34	509.3
Gain (Loss) on Sale of Investments	0.27	0.26	-	0.06	0.84	-
Gain (Loss) on Sale of Assets	-0.61	-0.33	0	-	-	-0.03
Asset Writedown	0.34	-	-6.35	-18.78	-0	-0
Other Unusual Items	16.14	15.47	28.77	5.35	8.45	5.06
Pretax Income	159.85	194.92	115.88	901.9	968.63	514.33
Income Tax Expense	24.96	28.14	10.58	128.33	132.87	79.36
Earnings From Continuing Operations	134.89	166.78	105.3	773.56	835.76	434.97
Minority Interest in Earnings	3.72	2.74	1.31	0.07	-2.17	0.18
Net Income	138.62	169.52	106.61	773.63	833.59	435.15
Net Income to Common	138.62	169.52	106.61	773.63	833.59	435.15
Net Income Growth	3.19%	59.01%	-86.22%	-7.19%	91.56%	1441.52%
Shares Outstanding (Basic)	107	105	107	107	87	80
Shares Outstanding (Diluted)	107	105	107	107	87	80
Shares Change (YoY)	0.82%	-1.23%	-0.10%	23.15%	8.33%	-0.01%
EPS (Basic)	1.30	1.61	1.00	7.25	9.62	5.44
EPS (Diluted)	1.30	1.61	1.00	7.25	9.62	5.44
EPS Growth	2.34%	61.00%	-86.21%	-24.64%	76.84%	1454.29%
Free Cash Flow	13.04	-116.23	74.96	524.29	707.92	388.38
Free Cash Flow Per Share	0.12	-1.10	0.70	4.91	8.17	4.86
Dividend Per Share	1.500	1.500	0.800	2.200	3.000	-
Dividend Growth	87.50%	87.50%	-63.64%	-26.67%	-	-
Gross Margin	49.36%	48.77%	39.02%	50.54%	61.20%	71.97%
Operating Margin	16.36%	20.16%	0.95%	39.59%	52.86%	60.81%
Profit Margin	27.09%	30.30%	24.11%	40.69%	45.85%	50.28%
Free Cash Flow Margin	2.55%	-20.78%	16.95%	27.58%	38.94%	44.88%
EBITDA	104.1	134.03	28.88	772.63	969.2	531.69
EBITDA Margin	20.34%	23.96%	6.53%	40.64%	53.31%	61.44%
D&A For EBITDA	20.41	21.27	24.68	19.9	8.2	5.48
EBIT	83.68	112.76	4.21	752.73	961	526.2
EBIT Margin	16.36%	20.16%	0.95%	39.59%	52.86%	60.81%
Effective Tax Rate	15.61%	14.44%	9.13%	14.23%	13.72%	15.43%
Revenue as Reported	511.66	559.4	442.11	1,901	1,818	865.37
Advertising Expenses	-	2.82	4.21	3.19	1.63	2.41

Source: S&P Global Market Intelligence. Standard template. Financial Sources.